Sartorius AG

EQS-News: Resolutions of the Annual General Meeting of Sartorius AG

Retrieved on: 
Wednesday, April 10, 2024
Sartorius AG, Sartorius, Annual general meeting, PwC, Supervisory board

At today’s virtual Annual General Meeting, the shareholders of Sartorius AG approved the proposals of the Executive Board and the Supervisory Board by a large majority, including the proposal to distribute a dividend of 0.74 euros per preference share and 0.73 euros per ordinary share.

Key Points: 
  • At today’s virtual Annual General Meeting, the shareholders of Sartorius AG approved the proposals of the Executive Board and the Supervisory Board by a large majority, including the proposal to distribute a dividend of 0.74 euros per preference share and 0.73 euros per ordinary share.
  • This press release contains forward-looking statements about the future development of the Sartorius Group.
  • Sartorius assumes no liability for updating such statements in light of new information or future events.
  • Sartorius shall not assume any liability for the correctness of this translation.

Resolutions of the Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.

Retrieved on: 
Wednesday, April 10, 2024
Sartorius AG, Annual

Resolutions of the Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.

Key Points: 
  • Resolutions of the Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.
    of Sartorius Stedim Biotech S.A.
    At today’s combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A., shareholders have granted discharge to all directors by a large majority and approved the renewal of the appointments as Directors of Susan Dexter and Anne-Marie Graffin for a three-year term of office.
  • This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group.
  • Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events.
  • Sartorius Stedim Biotech shall not assume any liability for the correctness of this release.

Sartorius Stedim Biotech SA: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Retrieved on: 
Friday, February 16, 2024
Sartorius AG, Disclosure, BOARD, Security (finance)

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • The person making the disclosure is a closely associated person mentioned of article 3.26) of Regulation (EU) No 596/2014 of April 16, 2014 on market abuse.
  • Please give the identity and functions of the person with whom the reporting person has close personal ties.
  • Position / status: Sartorius AG legal entity related to JOACHIM KREUZBURG, CHAIRMAN OF THE BOARD and RENE FABER, CEO
    This notification is an initial notification.

Sartorius Stedim Biotech releases Universal Registration Document 2023

Retrieved on: 
Friday, February 16, 2024
Sartorius AG, Annual, Euronext, Euronext Paris

Sartorius Stedim Biotech, a leading partner of the biopharma industry, has released its Universal Registration Document 2023 including the Annual Financial Report today.

Key Points: 
  • Sartorius Stedim Biotech, a leading partner of the biopharma industry, has released its Universal Registration Document 2023 including the Annual Financial Report today.
  • Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris.
  • Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies.

Sartorius Stedim Biotech: Information on Document Availability

Retrieved on: 
Friday, February 16, 2024
Sartorius AG, Bank statement, Euronext, Euronext Paris

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Sartorius Stedim Biotech Group’s Universal Registration Document 2023 is now available at:
    It contains the following information:
    - Consolidated financial statements for the year ended December 31, 2023
    Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris.
  • Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies.

Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Thursday, February 15, 2024
Biotechnology, Diabetes, Health, Other Health, Pharmaceutical, Stem Cells, Research, Medical Devices, Infectious Diseases, General Health, Science, COVID-19, Clinical Trials, Medical Supplies, Opus, Acquisition, Woman, Real-time, Starbright, Sartorius AG, Forecasting, MSI, Library, Sequoia, Growth, Table, PTC, QIAGEN, Nature, Kit, Antibody, Quality control, Safety, GAAP, RNA, Webcast, Patent, COVID, Policy, Bio-Rad Laboratories, Flow cytometry, EPS, PCR, Bank statement, Workflow, Infection, Bank

A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.

Key Points: 
  • A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.
  • There are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies.
  • The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on our reported financial results.
  • Investors should review the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.

EQS-News: The Supervisory Board of Sartorius AG proposes a dividend of 0.74 euros per preference share

Retrieved on: 
Friday, February 9, 2024
Sartorius, Supervisory board, Annual, Research, Vaccine, Sartorius AG, Laboratory, Acquisition, Quality control, Security (finance)

The Supervisory Board of Sartorius AG resolved at its meeting today to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 28, 2024, to pay a dividend of 0.74 euros per preference share and 0.73 euros per ordinary share for fiscal 2023.

Key Points: 
  • The Supervisory Board of Sartorius AG resolved at its meeting today to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 28, 2024, to pay a dividend of 0.74 euros per preference share and 0.73 euros per ordinary share for fiscal 2023.
  • Under this proposal, the total distributed profit would be 50.7 million euros.
  • This press release contains forward-looking statements about the future development of the Sartorius Group.
  • Sartorius assumes no liability for updating such statements in light of new information or future events.

Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual Shareholders’ Meeting

Retrieved on: 
Wednesday, February 7, 2024
Sartorius AG, Euronext Paris, Euronext, Annual

The Board of Directors of Sartorius Stedim Biotech S.A. resolved at today’s meeting to submit a proposal to the combined Annual Shareholders' Meeting to be held on March 26, 2024, to pay a dividend of 0.69 euros per share for fiscal 2023.

Key Points: 
  • The Board of Directors of Sartorius Stedim Biotech S.A. resolved at today’s meeting to submit a proposal to the combined Annual Shareholders' Meeting to be held on March 26, 2024, to pay a dividend of 0.69 euros per share for fiscal 2023.
  • The Board of Directors also approved the decision to submit to the Annual Shareholders’ Meeting the 2023 results of Sartorius Stedim Biotech which had already been published on a preliminary basis on January 26, 2024.
  • This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group.
  • Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events.

Sartorius Stedim Biotech S.A. announces an offering of approximately 1.2 billion euros of new shares without shareholders’ preferential subscription rights by means of an accelerated bookbuilding

Retrieved on: 
Tuesday, February 6, 2024
Financial services, Failure, Sartorius AG, Order, Person, European, Prospectus, European Economic Area, Council, Gross metropolitan product, Advertising, Risk, State, Sale, AMF, European Parliament, Equity carve-out, Finance, Security (finance)

This press release may not be published, distributed or released in South Africa, Australia, Canada or Japan.

Key Points: 
  • This press release may not be published, distributed or released in South Africa, Australia, Canada or Japan.
  • The release, publication or distribution of this press release in certain jurisdictions may be restricted by laws or regulations.
  • The issuance by the Issuer or the subscription of the Shares may be subject to legal and regulatory restrictions in certain jurisdictions.
  • This announcement may not be published, forwarded or distributed, directly or indirectly, in South Africa, Australia, Canada or Japan.

EQS-News: Sartorius expects profitable growth in 2024; double-digit annual sales revenue growth projected through to 2028

Retrieved on: 
Tuesday, January 30, 2024
CO2, Patient, Deleveraging, Forecasting, Research, Sartorius, Face, Electricity, Novasep, Public expenditure, Acquisition, Sartorius AG, Acceleration, Transfection, Weakness, Vaccine, News, Growth

Sartorius expects profitable growth in 2024; double-digit annual sales revenue growth projected through to 2028 (news with additional features)

Key Points: 
  • Sartorius expects profitable growth in 2024; double-digit annual sales revenue growth projected through to 2028 (news with additional features)
    The issuer is solely responsible for the content of this announcement.
  • Sales revenue in the Americas region was down 14.9 percent and accounted for around 38 percent of the Group total.
  • In the Asia | Pacific region, in particular, the pronounced weakness of the market in China had a significant impact, with sales revenue down 22.1 percent.
  • Sartorius intends to continue its profitable growth path in the long term and expects to grow faster than the market.